In a pioneering move, researchers at The Florey Institute have developed a novel method utilizing mRNA technology to directly target the tau protein, which plays a critical role in the development of Alzheimer's disease and other dementia-related conditions. This innovative approach marks the first time mRNA, widely recognized for its role in COVID-19 vaccines, has been applied to Alzheimer's disease, positioning The Florey as a leader in mRNA research.